However, the exclusion of the SOLOIST-WHF trial in order to restrict our analysis to the acute HF setting showed that SGLT-2 inhibitor produce a significant decrease in the risk for all-cause death among individuals with acute HF, equal to 42% (RR = 0.58, 95% CI; 0.35–0.95, I2 = 0%), as shown in Figure 2b. This evidence concerns the gene SLC5A2 and hydrops fetalis.